MA29265B1 - Derives de 3-aryl-1, 2-benzisoxazole, et leur utilisation comme medicaments contre le cancer - Google Patents

Derives de 3-aryl-1, 2-benzisoxazole, et leur utilisation comme medicaments contre le cancer

Info

Publication number
MA29265B1
MA29265B1 MA30161A MA30161A MA29265B1 MA 29265 B1 MA29265 B1 MA 29265B1 MA 30161 A MA30161 A MA 30161A MA 30161 A MA30161 A MA 30161A MA 29265 B1 MA29265 B1 MA 29265B1
Authority
MA
Morocco
Prior art keywords
aryl
nr5r6
nitro
halogen
cancer drugs
Prior art date
Application number
MA30161A
Other languages
English (en)
Inventor
Luc Bertin
Chantal Carrez
Fabienne Thompson
Patrick Maillet
Jean-Marie Ruxer
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35058405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29265(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MA29265B1 publication Critical patent/MA29265B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

L'INVENTION CONCERNE LES NOUVEAUX PRODUITS DE FORMULE (I): DANS LAQUELLE A1 ET A2 REPRÉSENTENT CH OU N; X REPRÉSENTE CRA OU N; Y REPRÉSENTE CRB OU N; R1, R2, R3 ET R4 IDENTIQUES OU DIFFÉRENTS REPRÉSENTENT NOTAMMENT HYDROGÈNE, HALOGÈNE, CYANO, NITRO, TRIFLUOROMÉTHYLE, OR5, SR5, NR5R6, C(O)R5, C(O)OR5, C(O) NR5R6, S(O)R5, S(O)2R5, S(O)NR5R6, S(O)2NR5R6, NR6C(O)R5, NR6C(O)OR5, ALKYLES, ALKÉNYLES, ALKYNYLES, ARYLES, HÉTÉROARYLES, ARALKYLES OU HÉTÉROARALKYLES, TOUS ÉVENTUELLEMENT SUBSTITUÉS; RA REPRÉSENTE NOTAMMENT HALOGÈNE, HYDROXYLE, ALCOXY, NITRO; RB REPRÉSENTE NOTAMMENT HYDROGÈNE, HALOGÈNE, CYANO, NITRO, TRIFLUOROMÉTHYLE, -W-(CI- C3ALKYLE)M- R5 ; R5 ET R6 REPRÉSENTE NOTAMMENT ALKYLE, ARALKYLE OU HÉTÉROARALKYLES ÉVENTUELLEMENT SUBSTITUÉS; CES PRODUITS ÉTANT SOUS TOUTES LES FORMES ISOMÈRES ET LES SELS, À TITRE DE MÉDICAMENTS.
MA30161A 2005-02-22 2007-08-23 Derives de 3-aryl-1, 2-benzisoxazole, et leur utilisation comme medicaments contre le cancer MA29265B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501801A FR2882361A1 (fr) 2005-02-22 2005-02-22 Nouveaux derives de 3-aryl-1,2-benzisoxazole, compositions les contenant et leur utilisation

Publications (1)

Publication Number Publication Date
MA29265B1 true MA29265B1 (fr) 2008-02-01

Family

ID=35058405

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30161A MA29265B1 (fr) 2005-02-22 2007-08-23 Derives de 3-aryl-1, 2-benzisoxazole, et leur utilisation comme medicaments contre le cancer

Country Status (19)

Country Link
US (1) US20080070960A1 (fr)
EP (1) EP1861381A1 (fr)
JP (1) JP2008531493A (fr)
KR (1) KR20070110102A (fr)
CN (1) CN101146780A (fr)
AR (1) AR053684A1 (fr)
AU (1) AU2006217799A1 (fr)
BR (1) BRPI0606178A2 (fr)
CA (1) CA2597781A1 (fr)
EA (1) EA200701798A1 (fr)
FR (1) FR2882361A1 (fr)
IL (1) IL185166A0 (fr)
MA (1) MA29265B1 (fr)
MX (1) MX2007010278A (fr)
NO (1) NO20074631L (fr)
TW (1) TW200640884A (fr)
UY (1) UY29390A1 (fr)
WO (1) WO2006090052A1 (fr)
ZA (1) ZA200707080B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US8969343B2 (en) 2012-12-19 2015-03-03 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884814B2 (en) * 2001-12-13 2005-04-26 Wyeth Phenyl benzisoxazoles as estrogenic agents
EA009919B1 (ru) * 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
KR101129215B1 (ko) * 2003-06-27 2012-04-13 교와 핫꼬 기린 가부시키가이샤 Ｈｓｐ90 패밀리 단백질 저해제
CA2536089A1 (fr) * 2003-08-20 2005-03-03 Eli Lilly And Company Modulateurs du recepteur active de la proliferation des peroxysomes (ppar)

Also Published As

Publication number Publication date
KR20070110102A (ko) 2007-11-15
ZA200707080B (en) 2008-11-26
EP1861381A1 (fr) 2007-12-05
WO2006090052A1 (fr) 2006-08-31
AR053684A1 (es) 2007-05-16
FR2882361A1 (fr) 2006-08-25
EA200701798A1 (ru) 2008-02-28
BRPI0606178A2 (pt) 2009-06-02
NO20074631L (no) 2007-11-20
CN101146780A (zh) 2008-03-19
US20080070960A1 (en) 2008-03-20
JP2008531493A (ja) 2008-08-14
AU2006217799A1 (en) 2006-08-31
TW200640884A (en) 2006-12-01
MX2007010278A (es) 2007-11-07
CA2597781A1 (fr) 2006-08-31
UY29390A1 (es) 2006-10-02
IL185166A0 (en) 2007-12-03

Similar Documents

Publication Publication Date Title
CY1120081T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
JP2015143283A5 (fr)
SE0402735D0 (sv) Novel compounds
MA31419B1 (fr) Derives de pyridine
MA29649B1 (fr) Nouveaux derives de 2,4- dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
HUP0402352A2 (hu) Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
CY1109370T1 (el) Παραγωγα οξαδιαζολονης ως ppar δελτα αγωνιστες
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
CY1111980T1 (el) Παραγωγα του αμιδιου τα οποια φερουν ενα υποκαταστατο του κυκλοπροπυλαμινοκαρβονυλιου και χρησιμευουν ως αναστολεις κυτταροκινης
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
Cholewiński et al. Synthesis of the inosine 5′-monophosphate dehydrogenase (IMPDH) inhibitors
CY1109376T1 (el) Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης
CY1108632T1 (el) Παραγωγα της 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline για θεραπεια της στειροτητας
MA29265B1 (fr) Derives de 3-aryl-1, 2-benzisoxazole, et leur utilisation comme medicaments contre le cancer
NO20055997L (no) Diarylmetylidenpiperidinderivater og deres anvendelse som opiodreseptoragonister
Kabi et al. Overview on Diverse Biological Activities of Benzisoxazole Derivatives
EE05300B1 (et) Akrloldistamtsiini derivaati sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat
HUP0203161A2 (hu) Benzamidinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
Ahmed et al. Synthesis and Anticonvulsant Activity of Some Substituted Azetidinone Derivatives
MA27091A1 (fr) Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA28426B1 (fr) Nouveaux composes 1,1-pyridinyloxycyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA201000807A1 (ru) Производные цефаломаннина, их приготовление, фармацевтические композиции и применение
MA28425B1 (fr) Nouveaux composes 1,1-pyridinylaminocyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent